Industry

Earnings Recap: Earth Science Tech Inc (ETST), Axim Biotechnologies Inc (AXIM), General Cannabis Corp (CANN)

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -9.72% and closed at $1.30, with the total traded volume of 78,554.00 shares. During last trade its minimum price was $1.12 and it gained its highest price of $1.41 and has a total of 40.91 million outstanding shares.

On February 9, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is proud to announce that four new scientists and doctors have joined the company’s Advisory Board. ETST strategy of recruiting industry experts to help expand and increase the Development of Cannabinoids’ Therapeutic Indications, R&D, Technology, IP and Treatments. These Four Distinguished Scientists and Doctors will serve on the board of advisory for Earth Science Tech and or its two wholly owned subsidiaries, Cannabis Therapeutics Inc., and Earth Science Pharmaceutical Inc.

Dr. Laurent Azoulay, PhD.

Laurent Azoulay, Ph.D., has joined both the Cannabis Therapeutics Inc. and Earth Science Pharmaceutical Inc. Advisory Boards. He is an Associate Professor of Oncology at McGill University, where he actively researches cancer pharmacoepidemiology, which includes evaluating the safety of cancer drugs at a societal level.

After receiving his PhD in 2007 from the Université de Montréal, he completed a postdoctoral fellowship in pharmacoepidemiology at the Department of Epidemiology, Biostatistics and Occupational Health, McGill University. He then joined the Gerald Department of Oncology as an Assistant Professor in 2009. In 2016, he was promoted to the rank of Associate Professor with a cross-appointment with the Department of Epidemiology, Biostatistics and Occupational Health.

Axim Biotechnologies Inc (OTCMKTS:AXIM) showing jumped of 11.16% and closed at $13.35, after gaining total volume of 63,248.00 shares. It earnings per share (EPS) is -$0.31 and it has total market capitalization of $687.43 million and a total of 51.49 million outstanding shares.

Axim Biotechnologies Inc (AXIM) on March 21, 2017 announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (AXIM), a world leader in cannabinoid research and development, has retained the services of Ora, Inc., a global Contract Research Organization (“CRO”), to perform the company’s upcoming product development (based on AXIM’ IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world’s leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases.

Ora will run the clinical programs under the supervision of Prof. Robert Ritch, Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE). Prof. Ritch is a world-renowned expert in ophthalmology and glaucoma in particular, and has joined AXIM’s Advisory Board in December 2016.

“It is exciting to see AXIM start on pre-clinical efforts alongside esteemed ophthalmology professionals to develop a cannabinoid based eye drop medication that may assist glaucoma sufferers,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “This partnership between AXIM and Ora is another new exciting milestone for AXIM’s clinical development program, as it continues to move forward finding cannabinoid-based solutions for conditions for which there is no effective treatment.

“Over three million Americans have glaucoma, which is the second leading cause of blindness in the world, according to the World Health Organization,” Dr. Titus continued. “We anticipate this partnership to enhance AXIM’s glaucoma and xerophtalmia (dry eye) products development, ultimately improving the well-being of patients across the globe who suffer with these conditions. At this time, it is anticipated that initial development and early stage trials will be performed in Europe but Ora, Inc. will be pushing to receive DEA approval for U.S. trials once the clinical development leads to human trials.”

“Despite new product approvals, glaucoma and dry eye remain ophthalmic diseases with significant unmet medical needs. Approximately 40% of glaucoma patients require more than one IOP-lowering medication. We hope that the development of new treatments with novel mechanisms of action will in turn reduce the risk of progression of visual field loss,” said David A. Hollander, MD, MBA, Chief Medical Officer of Ora. “Dry eye is one of the leading reasons for patient visits to eye care specialists.  Novel therapies that address the signs and symptoms of dry eye disease will be welcomed by both dry eye sufferers and physicians.”

General Cannabis Corp (OTCMKTS:CANN) increased 2.33% closed at $2.20 and traded with total volume of 97,569.00 shares, while the average trading remained 143,289.00 shares. During last trade its minimum price was $2.10 and it gained the highest price of $2.23. Its market capitalization was $41.57 million.

General Cannabis Corp. provides services to the regulated cannabis industry in the United States. The company engages in the acquisition and leasing of cultivation space and related facilities to licensed marijuana growers and dispensary owners; and provision of security services, including on-site professionals, video surveillance, and cash transport to licensed cannabis cultivators and retail shops. It also designs, distributes, and sells apparel featuring graphic designs; and offers consulting services to the cannabis industry that comprise obtaining licenses, compliance, cultivation, logistical support, facility design, and building services. In addition, General Cannabis Corp. provides shared office space, networking, and event services; and leases cultivation equipment and facilities. The company was formerly known as Advanced Cannabis Solutions, Inc. and changed its name to General Cannabis Corp. in June 2015. General Cannabis Corp. was founded in 2013 and is headquartered in Denver, Colorado.

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *